Mercado mundial de biopsia líquida: tendencias de la industria y pronóstico hasta 2031

Análisis y tamaño del mercado de biopsia líquida

En el mercado de la biopsia líquida, el control de la enfermedad residual mínima (ERM) representa una aplicación importante. Esto implica el uso de técnicas de biopsia líquida para detectar y analizar células cancerosas residuales o ADN en el torrente sanguíneo después del tratamiento. Este enfoque no invasivo ofrece una herramienta valiosa para evaluar la eficacia del tratamiento y predecir la probabilidad de recurrencia del cáncer. El desarrollo continuo de las tecnologías de biopsia líquida y su integración en la práctica clínica impulsa aún más el crecimiento y la adopción de soluciones de biopsia líquida para el control de la ERM en el mercado.

En noviembre de 2023, Illumina Inc. anunció TruSight Oncology 500 ctDNA v2, una versión avanzada de su ensayo de biopsia líquida diseñado para la elaboración de perfiles genómicos integrales en oncología. Esta versión mejorada promete una mayor sensibilidad y especificidad en la detección de mutaciones asociadas al cáncer a partir del ADN tumoral circulante.

El tamaño del mercado mundial de biopsia líquida se valoró en USD 2.31 mil millones en 2023 y se proyecta que alcance los USD 8 mil millones para 2031, con una CAGR del 16,8% durante el período de pronóstico de 2024 a 2031. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología del paciente, análisis de la cartera de proyectos, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado       

Market Definition

Liquid biopsy is a medical technique transforming diagnostics by analyzing biomolecules such as DNA, RNA, and proteins in bodily fluids such as blood. Unsuch as invasive traditional biopsies, it is non-invasive, offering vital diagnostic insights into conditions such as cancer without surgery. Although still evolving, liquid biopsies show immense promise in enhancing cancer detection and management, marking a significant leap in medical innovation.

Liquid Biopsy Market Dynamics

Drivers

• Rise in Integration of AI Enhances Accuracy of Cellular Data Extracted from Liquid Biopsy Samples

Artificial Intelligence (AI) is transforming liquid biopsy technology by enhancing its accuracy, efficiency, and predictive capabilities. Through advanced algorithms and machine learning, AI can analyze vast amounts of genetic, proteomic, and cellular data extracted from liquid biopsy samples. This enables early detection of diseases such as cancer, offering personalized treatment insights and monitoring disease progression. AI-driven liquid biopsy platforms streamline diagnostics, making them more accessible and cost-effective, thus driving market growth. With its ability to uncover actionable insights from complex biological data, AI is catalyzing the expansion of liquid biopsy applications in healthcare, leading to improved patient outcomes and driving the market forward.

In November 2020, NeoGenomics, Inc. launched a mobile phlebotomy service for liquid biopsy tests, leveraging AI-enhanced diagnostics such as InvisionFirst and NeoLAB. This initiative aligns with the growing trend of AI-driven liquid biopsy technologies, extending accessibility to patients through convenient sample collection at their locations. Partnering with phlebotomy companies for widespread coverage, NeoGenomics optimizes the efficiency of its AI-powered liquid biopsy solutions, driving market adoption and improving patient access to advanced diagnostics.

• Rising Healthcare Expenditure Promotes the Adoption of Liquid Biopsy Technologies

With greater investment in healthcare infrastructure and resources, there's heightened emphasis on advanced diagnostic tools such as liquid biopsies. These technologies offer non-invasive and efficient methods for cancer detection, monitoring, and personalized treatment planning. As healthcare systems strive to improve patient outcomes with the benefits of liquid biopsies in terms of early detection, treatment efficacy assessment, and minimal invasiveness make them an attractive option. Consequently, the rising healthcare expenditure acts as a catalyst for the widespread adoption and growth of the liquid biopsy market.

Opportunities

• Growing Demand for Non-Invasive Liquid Biopsy Techniques due to its Impact on Cancer Diagnosis

Over the last decade, traditional invasive methods have given way to non-invasive techniques such as liquid biopsy. This approach involves isolating tumor-derived components, such as circulating tumor cells and DNA, from bodily fluids for genomic and proteomic analysis. Consequently, the market is witnessing substantial growth as healthcare providers increasingly rely on these advanced, less intrusive methods for more accurate cancer detection and personalized treatment strategies.

• Growing Advancements in Precision Medicine due to Liquid Biopsy

Advancements in this field enable non-invasive detection and monitoring of diseases through analysis of circulating biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes. This approach facilitates early diagnosis, treatment selection, and monitoring of treatment response, enhancing patient outcomes. With its ability to provide real-time insights into disease progression and therapeutic efficacy, liquid biopsy holds immense potential for personalized medicine, driving growth in the liquid biopsy market as it becomes an indispensable tool in oncology and beyond.

Restraints/Challenges

• High Cost of Liquid Biopsy Tests Limits its Adoption among the Patients

Liquid biopsy tests often involve advanced technologies and specialized equipment, contributing to their expensive nature. Additionally, factors such as laboratory processing fees and the need for skilled personnel further elevate the overall cost. As a result, patients may encounter financial barriers, particularly in regions with limited access to healthcare resources or inadequate insurance coverage. The affordability gap hinders widespread adoption of liquid biopsy tests, despite their potential benefits in terms of early cancer detection and personalized treatment.

• Shortage of Skilled Professionals Limits the Scalability of Liquid Biopsy Techniques

Liquid biopsy, a non-invasive method for detecting biomarkers in bodily fluids such as blood, requires specialized training and expertise for accurate analysis and interpretation of results. The scarcity of qualified professionals capable of conducting these intricate tests limits the widespread adoption and scalability of liquid biopsy techniques, thereby constraining market growth. This bottleneck impedes the efficient utilization of liquid biopsy as a diagnostic tool in oncology and other fields, hindering its potential impact on healthcare outcomes.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In January 2022, QIAGEN's Biotech Grants program winners were announced, displaying the company's dedication to fostering partnerships with biotech and pharma firms. Supporting these businesses, QIAGEN aims to bolster their success in the market, contributing to its revenue growth strategy
• En enero de 2022, Exact Sciences Corporation amplió su cartera de diagnóstico del cáncer con la adquisición de Prevention Genetics, un laboratorio de pruebas genéticas. Esta medida estratégica permite a Exact Sciences incursionar en las pruebas de cáncer hereditario, complementando su oferta existente y mejorando su posición en el mercado de diagnóstico.
• En julio de 2021, Biocept Inc. obtuvo una patente en Corea del Sur para su tecnología Primer-Switch, un hito importante para el proveedor de servicios de diagnóstico molecular. Esta tecnología, basada en PCR en tiempo real y métodos asociados, permite la detección de mutaciones en el ADN tumoral circulante, lo que ayuda a la identificación de biomarcadores de cáncer raros y fortalece la posición de Biocept en el campo del diagnóstico del cáncer.

Alcance del mercado de la biopsia líquida

El mercado está segmentado en función del producto, el tipo de biomarcador, el tipo de muestra, el tipo analítico, el tipo de aplicación, la aplicación clínica, la tecnología, el usuario final y el canal de distribución. El crecimiento entre segmentos le ayuda a analizar nichos de crecimiento y estrategias para abordar el mercado y determinar sus áreas de aplicación principales y la diferencia en sus mercados objetivo.

Producto

• Instrumentos
• Consumibles y accesorios  
• Servicios y software

Tipo de biomarcador

• Células tumorales circulantes (CTCc)
• ADN libre circulante (CFDNA)
• ARN libre de células
• Vesículas extracelulares
• Exosomas
• Otros

Tipo de muestra

• Basado en muestras de sangre
• Basado en muestra de orina
• Muestras de saliva y otros fluidos tisulares
• Basado en muestras fecales
• Otros

Tipo Analítico

• Molecular
• Proteómica
• Histología/Imagenología

Tipo de aplicación

• Aplicaciones contra el cáncer
• Aplicaciones no relacionadas con el cáncer

Aplicación clínica

• Examen de rutina
• Evaluación del paciente
• Selección de terapia
• Seguimiento del tratamiento  
• Monitoreo de recurrencia
• Otros

Tecnología

• Análisis paralelo de múltiples genes
• Análisis de un solo gen

Usuario final

• Hospitales
• Laboratorios de referencia
• Centros de diagnóstico
• Centros de investigación e institutos académicos
• Otros

Canal de distribución

• Licitación directa
• Distribuidor externo
• Otros

Análisis y perspectivas regionales del mercado de biopsia líquida

El mercado se clasifica en nueve segmentos notables según el producto, el tipo de biomarcador, el tipo de muestra, el tipo analítico, el tipo de aplicación, la aplicación clínica, la tecnología, el usuario final y el canal de distribución.

Los países cubiertos en este informe de mercado son EE. UU., Canadá, México, Alemania, Reino Unido, Francia, Rusia, Italia, España, Turquía, Polonia, Bélgica, Países Bajos, Suiza, Dinamarca, Suecia, Noruega, Finlandia, resto de Europa, China, Japón, India, Australia, Corea del Sur, Nueva Zelanda, Singapur, Tailandia, Filipinas, Malasia, Indonesia, Vietnam, Taiwán, resto de Asia-Pacífico, Brasil, Argentina, resto de Sudamérica, Arabia Saudita, Emiratos Árabes Unidos, Sudáfrica, Egipto, Qatar, Kuwait, Omán, Bahréin y resto de Medio Oriente y África.

In North America, U.S. is expected to dominate the market due to the country's high prevalence of chronic conditions and a sizable geriatric population creates significant demand for nurse calling systems to support patient care. Additionally, the rise in healthcare expenditure in the U.S. underscores a growing investment in healthcare infrastructure and technology, including nurse calling systems. These factors collectively position the U.S. as a leader in driving market growth and innovation within the region, reflecting its commitment to improving patient outcomes and healthcare delivery.   

In Europe, Germany dominates the market due to the strong presence of key players such as F. Hoffmann-La Roche Ltd, QIAGEN, and Sysmex Inostics Inc. This dominance is attributed to Germany's robust research and development infrastructure, highly skilled workforce, and supportive government policies fostering innovation. The country's strategic geographical location within Europe also facilitates collaboration and access to markets across the continent. Consequently, Germany serves as a hub for cutting-edge research, technological advancements, and market leadership in the biotech and life sciences industries throughout Europe.

In Asia-Pacific, China dominates the market due to its ability to meet increasing demand, particularly from emerging markets. Leveraging its manufacturing capabilities and competitive pricing, Chinese companies have captured significant market share within the region. Furthermore, China's strategic focus on expanding its presence in emerging markets has contributed to its leadership position. This trend underscores China's emergence as a key player in the global liquid biopsy market, driven by both its production capabilities and growing demand from dynamic markets across Asia-Pacific.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Panorama competitivo y análisis del mercado de biopsia líquida

El panorama competitivo del mercado proporciona detalles de los competidores. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en I+D, las nuevas iniciativas de mercado, los sitios e instalaciones de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, las aprobaciones de productos, la amplitud y la variedad de productos, el dominio de las aplicaciones y la curva de vida útil del tipo de producto. Los puntos de datos proporcionados anteriormente solo están relacionados con el enfoque de la empresa en el mercado.

Algunos de los principales actores que operan en el mercado son:

• Thermo Fisher Scientific Inc. (Estados Unidos)
• Illumina, Inc. (Estados Unidos)
• BIOCEPT, INC. (EE.UU.)
• Laboratorios Bio-Rad, Inc. (Estados Unidos)
• Corporación de Ciencias Exactas (Estados Unidos)
• Menarini Silicon Biosystems (Italia)
• Epic Sciences (Estados Unidos)
• Laboratorios NeoGenomics (EE. UU.)
• mdxhealth (Bélgica)
• F. Hoffmann-La Roche Ltd (Suiza)
• QIAGEN (Países Bajos)
• Corporación Oncocyte (Estados Unidos)
• Johnson & Johnson Services, Inc. (Estados Unidos)
• PathAI, Inc. (Estados Unidos)
• Guardant Health (Estados Unidos)
• Corporación de laboratorio de América Holdings (Estados Unidos)
• ANGLE plc (Reino Unido)
• Natera, Inc. (Estados Unidos)
• Sysmex Inostics Inc. (Estados Unidos)
• STRECK (Estados Unidos)
• Predicción (EE.UU.)

SKU-10732